Adipose tissue, adipokines and aging;Tkanka tłuszczowa i adipokiny a proces starzenia

Polski Merkuriusz Lekarski

Volumn 40, Issue 236, 2016, Pages 122-128

  Adamiak, Paulina ^a   Łącka, Katarzyna ^a  

^a POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

Author keywords

adipokines; adipose tissue; aging

Indexed keywords

ADIPOCYTOKINE; C REACTIVE PROTEIN;

ADIPOSE TISSUE; AGING; BLOOD; CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; HUMAN; INSULIN RESISTANCE; METABOLISM; PHYSIOLOGY;

ADIPOKINES; ADIPOSE TISSUE; AGING; C-REACTIVE PROTEIN; CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; HUMANS; INSULIN RESISTANCE;

EID: 84973410987     PISSN: 14269686     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (122)

1. Adamczak A, Wiecek A: The adipose tissue as an endocrine organ. Semin Nephrol, 2013; 33(1): 2-13.
2. Ahima RS, Osei SY: Leptin signaling. Physiol Behav, 2004; 81(2): 223-241.
3. Akinici M, Kosova F, Cetin B, et al.: Leptin levels in thyroid cancer. Asian J Surg, 2009; 32(4): 216-223.
4. Aktas B, Yilmaz Y, Eren F, et al.: Serum levels of vaspin, obestatin, and apelin-36 in patients with non-alkoholic fatty liver disease. Metabolism, 2011; 60: 544-549.
5. Alfadda AA, Sallam RM, Chishti MA, et al.: Differential patterns of serum concentration and adipose tissue expression of chemerin in obesity: adipose depot specificity and gender dimorphism. Mol Cells, 2012; 33: 591-596.
6. Allison MA, Ix JH, Morgan C, et al.: Higher leptin is associated with hypertension: the Multi-Ethnic Study of Atherosclerosis. J Hum Hipertens, 2013; 27(10): 617-622.
7. Arai Y, Takayama M, Abe Y, et al.: Adipokines and aging. J Atheroscler Thromb, 2011; 18: 545-550.
8. Arita Y, Kihara S, Ouchi N, et al.: Paradoxical decrease of an adiposespecific protein, adiponectin, in obesity. Biochem Biophys Res Commun, 1999; 257(1): 79-81.
9. Ataseven A, Kesli R.: Novel inflammatory markers in psoriasis vulgaris: vaspin, vascular adhesion protein-1 (vap-1), and ykl-40. Ital Dermatol Venereol, 2014; w druku.
10. Atzmon G, Pollin TI, Crandall J, et al.: Adiponectin levels and genotype: a potential regulator of life span in humans. J Gerontol A Biol Sci Med Sci, 2008; 63(5): 447-453.
11. Balaskó M, Soós S, Székely M, et al.: Leptin and aging: Review and questions with particular emphasis on its role in the central regulation of energy balance. J Chem Neuroanat, 2014; 61-62: 248-255.
12. Bao JP, Jiang LF, Chen WP, et al.: Expression of vaspin in the joint and the levels in the serum and synovial fluid of patients with osteoarthritis. Int J Clin Exp Med, 2014; 7(10): 3447-3453.
13. Baran A, Flisiak I, Jaroszewicz J, i wsp.: Effects of psoriasis activity on serum adiponectin and lepton levels. Postepy Dermatol Alergol, 2015; 32(2): 101-106.
14. Barth S, Klein P, Horbach T, et al.: Expression of neuropeptide Y, omentin and visfatin in visceral and subcutaneous adipose tissues in humans: relation to endocrine and clinical parameters. Obes Facts, 2010; 3: 245-251.
15. Baumgartner RN, Waters DL, Morley JE, et al.: Age-related changes in sex hormones affect the sex difference in serum leptin independently of changes in body fat. Metabolism, 1999; 48(3): 378-384.
16. Beni AA, Etemadifar M, Rezaei A, et al.: Role of adiponectin in multiple sclerosis. Mult Scler Relat Disord, 2014; 3(6): 746.
17. Bik W, Baranowska-Bik A, Wolinska-Witort E, et al.: Assessment of adiponectin and its isoforms in Polish centenarians. Exp Gerontol, 2013; 48(4): 401-407.
18. Blüher M.: Vaspin in obesity and diabetes: pathophysiological and clinical significance. Endocrine, 2012; 41(2): 176-182.
19. Bobbert T, Schwarz F, Fischer-Rosinsky A, et al.: Chemerin and prediction of Diabetes mellitus type 2. Clin Endocrinol (Oxf), 2015; 82(6): 838-843.
20. Briffa JF, McAinch AJ, Poronnik P, et al.: Adipokines as a link between obesity and chronic kidney disease. Am J Physiol Renal Physiol, 2013; 305(12): F1629-1636.
21. Broch M, Augguet MT, Ramirez R, et al.: Parallel downregulation of retinol-binding protein-4 (RBP4) and adiponectin expression in subcutaneous adipose tissue of non-morbidly obese subjects. Eur J Endocrinol, 2009; 161(1): 87-94.
22. Carbone F, La Rocca C, Matarese G. Immunological functions of leptin and adiponectin. Biochimie, 2012; 94(10): 2082-2088.
23. Carter S, Caron A, Richard D, et al.: Role of leptin resistance in the development of obesity in older patients. Clin Interv Aging, 2013; 8: 829-844.
24. Choi SH, Kwak SH, Lee Y, et al.: Plasma vaspin concentrations are elevated in metabolic syndrome in men and are correlated with coronary atherosclerosis in women. Clin Endocrinol (Oxf), 2011; 75(5): 628-635.
25. Christou GA, Tselepis AD, Kiortsis DN. The metabolic role of retinol binding protein 4: an update. Horm Metab Res, 2012; 44(1): 6-14.
26. Cinar N, Gurlek A. Association between novel adipocytokines adiponectin, vaspin, visfatin, and thyroid: An experimental and clinical update. Endocr Connect, 2013; 2(4): R30-38.
27. Cnop M, Havel PJ, Utzschneider KM, et al.: Reletionship of adiponectin to body fat distribution, insulin sensitivity and plasma lipoproteins: evidence for independent roles of age and sex. Diabetologia, 2003; 46(4): 459-469.
28. Coimbra S, Brandǎo Proenca J, Santos-Silva A, et al.: Adiponectin, leptin, and chemerin in elderly patients with type 2 diabetes mellitus: a close linkage with obesity and length of the disease. Biomed Res Int, 2014; 2014: 701915.
29. Considine RV, Sinha MK, Heiman ML, et al.: Serum immunoreactiveleptin concentrations in normal-weight and obese humans. N Engl J Med, 1996; 334: 292-295.
30. Coppack SW: Pro-inflammatory cytokines and adipose tissue. Proc Nutr Soc, 2001; 60: 349-356.
31. Costford SR, Bajpeyi S, Pasarica M, et al.: Skeletal muscle NAMPT is induced by exercise in humans. Am J Physiol Endocrinol Metab, 2010; 98: E117-126.
32. Cypess AM, Lehman S, Williams G, et al.: Identification and importance of brown adipose tissue in adult humans. N Engl J Med, 2009; 360: 1509-1517.
33. De Pergola G, Silvestris F.: Obesity as a major risk factor for cancer. J Obes, 2013; 1-11.
34. De Souza Batista CM, Yang RZ, Lee MJ, et al.: Omentin plasma levels and gene expression are decreased in obesity. Diabetes, 2007; 56: 1655-1661.
35. Emilsson V, Liu YL, Cawthorne MA, et al.: Expression of the functional leptin receptor mRNA in pancreatic islets and direct inhibitory action of leptin on insulin secretion. Diabetes, 1997; 46: 313-316.
36. Erdogan S, Sezer S, Baser E, et al.: Evaluating vaspin and adiponectin in postmenopausal women with endometrial cancer. Endocr Relat Cancer, 2013; 20(5): 669-675.
37. Esteghamati A, Noshad S, Mousavizadeh M, et al.: Association of Vaspin with Metabolic Syndrome: The Pivotal Role of Insulin Resistance. Diabetes Metab J, 2014; 38: 143-149.
38. Fatima SS, Rehman R, Baig M, et al.: New roles of the multidimensional adipokine: chemerin. Peptides, 2014; 62: 15-20.
39. Feng R, Li Y, Wang C, et al.: Higher vaspin levels in subjects with obesity and type 2 diabetes mellitus: a meta-analysis. Diab Res Clin Pract, 2014; 106(1): 88-94.
40. Filippi BM, Lam TK: Leptin and aging. Aging, 2014; 6(2): 82-83.
41. Fisher FM, Trujillo ME, Hanif W, et al.: Serum high molecular weight complex of adiponectin correlates better with glucose tolerance than total serum adiponectin in Indo-Asian males. Diabetology, 2005; 48(6): 1084-1087.
42. Folch J, Pedrós I, Patraca I, et al.: Neuroprotecitive and anti-ageing role of leptin. J Mol Endocrinol, 2012; 49(3): R149-156.
43. Foster MC, Hwang SJ, Porter SA, et al.: Fatty kindey, hypertension, and chronic kidney disease: the Framingham heart study. Hypertension, 2011, 58: 784-790.
44. Friedman JM, Halaas JL: Leptin and the regulation of body weight in mammals. Nature, 1998; 395: 763-770.
45. Fukuhara A, Matsuda M, Nishizawa M, et al.: Visfatin: a protein secreted by visceral FAT that mimics the effect of insulin. Science, 2005; 307: 426-430.
46. Gallagher D, Kuznia P, Heshka S, et al.: Adipose tissue in muscle: a novel depot similar to visceral adipose tissue. Am J Clin Nutr, 2005; 81: 903-910.
47. Garten A, Petzold S, Barnikol-Oettler A, et al.: Nicotinamide phosphoribosyltransferase (NAMPT/PBEF/visfatin) is constitutively released from human hepatocytes. Biochem Biophys Res Commun, 2010; 391: 376-381.
48. Gong TT, Wu QJ, Wang YL, et al.: Circulating adiponectin, leptin and adiponectin-leptin ratio and endometrial cancer risk: Evidence from a meta-analysis of epidemiologic studies. Int J Cancer, 2015; w druku.
49. Goodpaster BH, Carlson CL, Visser M, et al.: Attenuation of skeletal muscle mass and strength in the elderly: the Health ABC Study. J Appl Physiol, 2001; 90: 2157-2165.
50. Goralski KB, McCarthy TC, Hanniman EA, et al.: Chemerin, a novel adipokine that regulates adipogenesis and adipocyte metabolism. J Biol Chem, 2007; 282: 28175-28188.
51. Graham TE, Yang Q, Blueher M, et al.: Retinol-binding protein 4 and insulin resistance in lean, obese and diabetic subjects. N Engl J Med, 2006; 354: 2552-2563.
52. Gürsoy G, Kirnap N, Esbah O, et al.: The relationship between plasma omentin-1 levels and insulin resistance in newly diagnosed type 2 diabetic women. Clin Rev Opinions, 2010; 2(4): 49-54.
53. Gustafson DR.: Adiposity hormones and dementia. J Neurol Sci, 2010; 299(1-2): 30-34.
54. Heiker JT.: Vaspin (serpinA12) in obesity, insulin resistance and inflammation. J Pept Sci, 2014; 20(5): 299-306.
55. Hida K, Wada J, Eguchi J, et al.: Visceral adipose tissue-derived serine protease inhibitor: a unique insulin - sensitizing adipocytokine in obesity. Proc Natl Acad Sci USA, 2005; 102: 10610-10615.
56. Ingelsson E, Sundström J, Melhus H, et al.: Circulating retinol-binding protein 4, cardiovascular risk factors and prevalent cardiovascular disease in elderly. Athelosclerosis, 2009; 206(1): 239-244.
57. Ismail SA, Mohamed SA.: Serum levels of visfatin and omentin-1 in patients with psoriasis and their relation to disease severity. Br J Dermatol, 2012; 167: 436-439.
58. Jaikanth C, Gurumurthy P, Cherian KM, et al.: Emergence of omentin as a pleiotropic adipocytokine. Exp Clin Endocrinol Diabetes, 2013; 121(7): 377-383.
59. Khabour OF, Mesmar FS, Alatoum MA, et al.: Associations of polymorphisms in adiponectin and leptin genes with men's longevity. Aging Male, 2010; 13(3): 188-193.
60. Kolovou G, Kolovou V, Vasiliadis I, et al.: Ideal lipid profile and genes for an extended life span. Curr Opin Cardiol, 2011; 26(4): 348-355.
61. Kotani K, Tokunaga K, Fujioka S, et al.: Sexual dimorphism of agerelated changes in whole-body fat distribution in the obese. Int J Obes Relat Metab Disord, 1994; 18: 207-212.
62. Lago F, Gómez R, Gómez-Reino JJ, et al.: Adipokines as novel modulators of lipid metabolism. Trends Biochem, 2009; 34: 500-510.
63. Lee Y, Hirose H, Ohneda M, et al.: Beta-cell lipotoxicity in the pathogenesis of non-insulin-dependent diabetes mellitus of obese rats: impairment in adipocyte-beta cell relationships. Proc Natl Acad Sci USA, 1994; 91: 10878-10882.
64. Li Q, Chen R, Moriya J, et al.: A novel adipocytokine, visceral adipose tissue-derived serine protease inhibitor (vaspin), and obesity. J Int Med Res, 2008; 36(4): 625-629.
65. Li Y, Shi B, Li S.: Association between Serum Chemerin Concentrations and Clinical Indices in Obesity or Metabolic Syndrome: a Metaanalysis. Plos One, 2014; 9(12): e113915.
66. Lobo JC, Aranha LN, Moraes C, et al.: Linking zinc and leptin in chronic kidney disease: future directions. Biol Trace Elem Res, 2012; 146(1): 1-5.
67. Maggio AB, Belli DC, Puiqdefabregas JW, et al.: High bone density in adolescents with obesity is related to fat mass and serum leptin concentrations. J Pediatr Gastroenterol Nutr, 2014; 58(6): 723-728.
68. Malin SK, Navaneethan SD, Mulya A, et al.: Exercise-induced lowering of chemerin is associated with reduced cardiometabolic risk and glucose- stimulated insulin secretion in older adults. J Nutr Health Aging, 2014; 18(6): 608-615.
69. Margetic S, Gazzola C, Pegg GG, et al.: Leptin: a review of its peripheral actions and interactions. Int J Obes Relat Metab Disord, 2002; 26: 1407-1433.
70. Morisaki T, Takeshima F, Fukuda H, et al.: High serum vaspin concentrations in patients with ulcerative colitis. Dig Dis Sci, 2014; 59(2): 315-321.
71. Nalabolu MR, Palasamudram K, Jamil K.: Adiponectin and leptin molecular actions and clinical significance in breast cancer. Int J Hematol Oncol Stem Cell Res, 2014; 8(1): 31-40.
72. Niedźwiecka B, Jagielska G, Bartoszewicz Z, i wsp.: Assessment of neuropeptide Y, leptin and leptin-receptor concentrations in teenagers suffering from anorexia nervosa. Ginekol Pol, 2013; 84(4): 268-276.
73. Olszanecka-Glinianowicz M, Handzlik-Orlik G, Orlik B, i wsp.: Adipokines in the pathogenesis of idiopathic inflammatory bowel disease. Endokrynol Pol, 2013; 64(3): 226-231.
74. Olszanecka-Glinianowicz M, Owczarek A, Bozentowicz-Wikarek M, et al.: Relationship between circulating visfatin/NAMPT, nutritional status and insulin resistance in an elderly population - results from the PolSenior substudy. Metabolism, 2014; 63(11): 1409-1418.
75. Panagiotou G, Mu L, Na B, et al.: Circulating irisin, omentin-1, and lipoprotein subparticles in adults at higher cardiovascular risk. Metabolism, 2014; 63(10): 1265-1271.
76. Paz-Filho G, Wong ML, Licinio J: Ten years of leptin replacement therapy. Obes Rev, 2011; 12(5): 315-323.
77. Prentice AM, Jebb SA.: Beyond body mass index. Obes Rev, 2001; 2: 141-147.
78. Qian H, Azain MJ, Compton MM, et al.: Brain administration of leptin causes deletion of adipocytes by apoptosis. Endocrinology, 1998; 139: 791-794. 30
79. Revollo JR, Körner A, Mills KF, et al.: Nampt/PBEF/Visfatin regulates insulin secretion in beta cells as a systemic NAD biosynthetic enzyme. Cell Metab, 2007; 6: 363-375.
80. Romacho T, Sánchez-Ferrer CF, Peiró C.: Visfatin/Nampt: an adipokine with cardiovascular impact. Mediat Inflamm, 2013; 2013: 946427.
81. Rosenbaum M, Leibel RL.: 20 years of leptin: role of leptin in energy homeostasis in humans. J Endocrinol, 2014; 223(1): T83-96.
82. Roszkowska-Gancarz M, Jonas M, Owczarz M, et al.: Age-related changes of leptin and leptin receptor variants in healthy elderly and longlived adults. Geriatr Gerontol Int, 2015; 15(3): 365-371.
83. Saisho Y, Butler AE, Meier JJ, et al.: Pancreas volumes in humans from birth to age on hundred taking into account sex, obesity, and presence of type 2 diabetes. Clin Anat, 2007. 20: 933-942.
84. Samal B, Sun Y, Stearns G, et al.: Cloning and characterization of the cDNA encoding a novel human pre-B-cell colony-enhancing factor. Mol Cell Biol, 1994; 14: 1431-1437.
85. Schroeter MR, Stein S, Heida NM, et al.: Leptin promotes the mobilization of vascular progenitor cellsand neovascularization by NOX2-mediated activation of MMP9. Cardiovasc Res, 2012; 93: 170-180.
86. Shackelford RE, Mayhall K, Maxwell NM, et al.: Nicotinamide phosphoribosyltransferase in malignancy: a review. Genes Cancer, 2013; 4(11-12): 447-456.
87. Sharma S, Adrogue JV, Golfman L, et al.: Intramyocellular lipid accumulation in the failing human heart resembles the lipotoxic rat heart. FASEB J, 2004; 18: 1692-1700.
88. Shen W, Wang Z, Punyanita M, et al.: Adipose tissue qualification by imaging methods: a proposed classification. Obes Res, 2003; 11: 5-16.
89. Shibata R, Ouchi N, Kikuchi R et al.: Circulating omentin is associated with coronary artery disease in men. Atherosclerosis, 2011; 219: 811-814.
90. Shurk T, Alberti-Huber C, Herder C, et al.: Relationship between adipocyte size and adipokine expression and secretion. J Clin Endocrinol Metab, 2007; 92: 1023-1033.
91. Silaghi A, Piercecchi-Marti MD, Grino M, et al.: Epicardial adipose tissue extent: relationship with age, body fat distribution, and coronaropathy. Obesity, 2008; 16: 2424-2430.
92. Suh JB, Kim SM, Cho GJ, et al.: Elevated serum retinol-binding protein 4 is associated with insulin resistance in older women. Metabolism, 2010; 59(1): 118-122.
93. Sun Z, Lei H, Zhang Z.: Pre-B cell colony enhancing factor (PBEF), a cytokine with multiple physiological functions. Cytokine Growth Factor Rev, 2013; 24(5): 433-442.
94. Szczepańska M, Machura E, Adamczyk P, i wsp.: Evaluation of adipocytokines in children with chronic kidney disease. Endokrynol Pol, 2015; 66(2): 100-107.
95. Takashima N, Tomoike H, Iwai N. Retinol-binding protein 4 and insulin resistance. N Engl J Med, 2006; 355: 1392.
96. Tamori Y, Sakaue H, Kasuga M. RBP4, an unexpected adipokine. Nature Med, 2006; 12: 30-31.
97. Tan BK, Adya R, Randeva HS: Omentin: A Novel Link Between Inflammation, Diabesity and Cardiovascular Disease. Trends Cardiovasc Med, 2010; 20(5): 143-148.
98. Tchkonia T, Giorgadze N, Pirtskhalava T, et al.: Fat depot-specific characteristics are retained in strains derived from single human preadipocytes. Diabetes, 2006; 55: 2571-2578.
99. Trayhurn P, Beattie JH.: Physiological role of adipose tissue: white adipose tissue as an endocrine and secretory organ. Proc Nutr Soc, 2001; 60: 329-339.
100. Tsoukas MA, Farr OM, Mantozoros CS. Leptin in congenital and HIVassociated lipodystrophy. Metabolism, 2014; 64(1): 47-59.
101. Wallace AM, McMahon AD, Packard CJ, et al.: Plasma leptin and the risk of cardiovascular disease in the west of Scotland coronary prevention study (WOSCOPS). Circulation, 2001; 104: 3052-3056.
102. Wang JL, Chinookoswong N, Scully S, et al.: Differential effects of leptin in regulation of tissue glucose utilization in vivo. Endocrinology, 1999; 140(5): 2117-2124.
103. Wang LY, Wei L, Yu HY, et al.:. Relationship of serum chemerin to obesity and type 2 diabetes mellitus. J Chin Med Assoc, 2009; 89: 235-238.
104. Wittamer V, Franssen JD, Vulcano M, et al.:. Specific recruitment of antigen-presenting cells by chemerin, a novel processed ligand from human inflammatory fluids. J Exp Med, 2003; 198: 977-985.
105. Wong GW, Wang J, Hug C, et al.: A family of Acrp30/adiponectin structural and functional paralogs. Proc Natl Acad Sci U S A, 2004; 101(28): 10302-10307.
106. Wu Y, Li H, Loss RJ, et al.: RBP4 variants are significantly associated with plasma RBP4 levels and hypertriglyceridemia risk in Chinese Hans. J Lipid Res, 2009; 50: 1479-1486.
107. Xie H, Tang SY, Luo XH, et al.: Insulin-like effects of visfatin on human osteoblasts. Calcif Tissue Int, 2007; 80: 201-210.
108. Yamauchi T, Kadowaki T: Adiponectin receptor as a key player in healthy longevity and obesity - related diseases. Cell Metab, 2013; 17(2): 185-196.
109. Yan P, Liu D, Long M, et al.: Changes of serum omentin levels and relationship between omentin and adiponectin concentrations in type 2 diabetes mellitus. Exp Clin Endocrinol Diabetes, 2011; 119: 257- 263.
110. Yan Q, Zhang Y, Hong J, et al.: The association of serum chemerin level with risk of coronary artery disease in Chinese adults. Endocrine, 2012; 41: 281-288.
111. Yang Q, Graham TE, Mody N et al.: Serum retinol binding protein 4 contributes to insulin resistance in obesity and type 2 diabetes. Nature, 2005; 436: 356-362.
112. Yin CG, Jiang L, Tang B, et al.: Prognostic significance of plasma visfatin levels in patients with ischemic stroke. Peptides, 2013; 42: 101-104.
113. Yin J, Hou P, Wu Z, et al.: Decreased levels of serum omentin-1 in patients with inflammatory bowel disease. Med Sci Monit, 2015; 21: 118-122.
114. Yoo HJ, Hwang SY, Hong HC et al.: Association of circulating omentin- 1 level with arterial stiffness and carotid plaque in type 2 diabetes. Cardiovasc Diabetol, 2012; 10: 103.
115. Youn BS, Kloting N, Kratzsch J, et al.: Serum vaspin concentrations in human obesity and type 2 diabetes. Diabetes, 2008; 57: 372-377.
116. Zamboni M, Mazzali G, Zoico E, et al.: Health consequences of obesity in the elderly: a review of four unresolved questions. Int J Obes Relat Metab Disord, 2005; 29: 1011-1029.
117. Zhang Y, Proenca R, Maffei M, et al.: Positional cloningof the mouse obese gene and its human homologue. Nature, 1994; 372(6505): 425-432.
118. Zhao LR, Du YJ, Chen L, et al.: Omentin-1 promotes the growth of neural stem cells via activation of Akt signaling. Mol Med Rep, 2015; 11(3): 1859-1864.
119. Zhou BO, Yue R, Murphy MM, et al.: Leptin-receptor-expressing mesenchymal stromal cells represent the main source of bone formed by adult bone marrow. Cell Stem Cell, 2014; 15(2): 154-168.
120. Zhou JY, Chan L, Zhou SW: Omentin: Linking Metabolic Syndrome and Cardiovascular Disease. Curr Vasc Pharmacol, 2014; 12: 136-143.
121. Zhu J, Schott M, Liu R, et al.: Intensive glycemic control lowers plasma visfatin levels in patients with type 2 diabetes. Horm Metab Res, 2008; 40: 801-805.
122. Zoico E, Di Francesco V, Bissoli L, et al.: Interrelationships between leptin resistance, body composition, and aging in elderly women. J Am Geriatr Soc, 2008; 56(9): 1768-1769.